Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-25-050063
Filing Date
2025-05-16
Accepted
2025-05-16 17:00:17
Documents
1
Period of Report
2025-05-09

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2515132-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2515132-1_3seq1.xml 3 4129
  Complete submission text file 0001104659-25-050063.txt   5669
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Issuer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ANNOVIS BIO, INC. 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address
Walsh Andrew (Reporting) CIK: 0002068849 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39202 | Film No.: 25960275